Kyntra Bio (KYNB) reported financial results for the fourth quarter and full year 2025, reflecting a decline in revenue and provided an update on the pipeline developments ahead.
For the fourth quarter of 2025, the firm incurred a net loss of $14.22 million, or $3.51 per share, compared with a net profit of $17.98 million, or $4.46 per share, in the year-ago quarter.
Net loss from continuing operations widened to $14.61 million, or $3.61 per share, from $8.67 million, or $2.15 per share, in the prior year.
Total revenue decreased to $1.28 million from $3.14 million in the prior year.
For the full year 2025, the firm swung to a net profit of $183.45 million, or $45.37 per share, from a net loss of $47.58 million, or $11.89 per share, in the prior year.
Net loss from continuing operations was $58.20 million, or $14.40 per share, from $153.10 million, or $38.26 per share, in the year ago.
Total revenue declined to $6.44 million from $29.62 million in the prior year.
Pipeline Updates
Kyntra Bio's investigational product pipeline includes Roxadustat for the treatment of anaemia in chronic kidney disease (CKD) and lower-risk myelodysplastic syndromes (LR-MDS), FG-3246 for metastatic castration-resistant prostate cancer (mCRPC) and other tumour types, and FG-3180, a diagnostic PET imaging agent.
The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
-Roxadustat
Kyntra Bio's Roxadustat (EVRENZO), an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis (red blood cell production).
It is approved in Europe, Japan, China, and numerous other countries for the treatment of anaemia in adult patients with CKD, including those on dialysis and those not on dialysis.
In the U.S, the company continues to evaluate the development plan for the Phase 3 trial of Roxadustat in anaemia associated with lower-risk myelodysplastic syndromes.
The company is currently exploring the opportunity to develop Roxadustat internally or with a strategic partner, with the goal of starting the Phase 3 trial in the second half of 2026.
FG-3246 and FG-3180
Kyntra Bio's FG-3246 (FOR46) is an antibody-drug conjugate, exclusively licensed from Fortis Therapeutics, and is being developed by Kyntra Bio for mCRPC and potentially other tumour types.
FG-3180 is a diagnostic PET imaging agent that uses CD46-targeting antibody, combined with a Zr tracker, and is currently being evaluated as a biomarker to inform patient selection.
According to the firm, the Phase 2 monotherapy trial of FG-3246 in mCRPC is actively enrolling and remains on track for interim analysis in the second half of 2026.
And this program also includes the development of FG-3180, an associated CD46-targeted PET biomarker.
Kyntra Bio ended 2025 with reported cash, cash equivalents totalling $109.4 million, and is expected to fund its operating plans into 2028.
KYNB has traded between $4.85 and $12.60 in the last year. The stock closed Monday's trade at $7.00, up 0.43%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.